Swedish Orphan Biovitrum Investor Relations Material
Latest events
Q1 2025
Swedish Orphan Biovitrum
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Swedish Orphan Biovitrum
Access all reports
Segment Data
Access more data
Revenue by
Business area
Haematology
Immunology
Specialty Care
Expenses by
Financials
Swedish Orphan Biovitrum AB, an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company operates through three segments: Haemophilia & Hereditary Diseases, Inflammation & Immunology, and Other. It offers Alprolix for hemophilia B; Elocta to treat hemophilia A; Doptelet for thrombocytopenia; Kineret for rheumatoid arthritis; Thiola for cystinuria; Xultophy Cartridge that is used with Flexpen for treatment of diabetes; and Velphoro for hyperphosphatemia.
Key slides for Swedish Orphan Biovitrum
Q4 2024
Swedish Orphan Biovitrum
Q1 2025
Swedish Orphan Biovitrum
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
SOBI
Country
🇸🇪 Sweden